Dr. Thomas Cannell, President and CEO of Sesen Bio, and Dr. Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity “Horizons in Oncology” Virtual Conference Apr 8, 2021 08:55AM
Sesen Bio, Inc (SESN) Likely to See Priority Review for Vicineum, Canaccord Genuity Considers a "Must-Own for 2021" Jan 25, 2021 08:35AM
Sesen Bio (SESN) Vicineum might reach $1B in annual US peak sales by 2025 - Canaccord Genuity Sep 24, 2020 09:32AM
Sesen Bio to Present Regulatory and Business Development Update at the Canaccord Genuity 40th Annual Growth Conference Aug 5, 2020 04:15PM
Sesen Bio to Present at the Canaccord Genuity 39th Annual Growth Conference Jul 31, 2019 07:30AM


Jun 19, 2019 08:02AM Sesen Bio (SESN) Prices 20.41M Share & Warrants Offering at $1.47/Unit
Jun 19, 2019 08:00AM Sesen Bio Announces Pricing of Public Offering of Common Stock and Warrants
Jun 18, 2019 04:18PM Sesen Bio (SESN) Plans Public Offering of Common Stock and Warrants
Jun 18, 2019 04:17PM Sesen Bio Announces Proposed Public Offering of Common Stock and Warrants
Aug 2, 2018 06:30AM Sesen Bio to Present at the Canaccord Genuity 38th Annual Growth Conference
Jul 9, 2018 09:00AM Pre-Open Movers 07/09: (MBVX) (HELE) (GRPN) Higher; (CTIC) (PETS) (PG) Lower (more...)
Jul 9, 2018 05:21AM Canaccord Genuity Starts Sesen Bio, Inc (SESN) at Buy
Jun 4, 2018 04:01PM Sesen Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares of Common Stock
May 31, 2018 05:48AM Sesen Bio (SESN) Prices 22.22M Share Common Offering at $1.80/Sh
May 30, 2018 09:22PM Sesen Bio Announces Pricing of Public Offering of Common Stock
May 30, 2018 04:01PM Sesen Bio (SESN) Announces Proposed Common Share Offering
May 30, 2018 04:00PM Sesen Bio Announces Proposed Public Offering of Common Stock